Schizophrenia is a clinical syndrome of variable, but profoundly disruptive psychopathology that involves cognition, emotion, perception, and other aspects of behavior. Despite marked advances in psychopharmacological management, there is no "quantum leap" in the etiopathogenetic processes of schizophrenia and as yet no pinpointed theory exist or substantiate the causal association to one specific reason. A central conceptual issue in the investigation of the etiology of schizophrenia is whether schizophrenia is a neurodevelopmental or a neurodegenerative disorder.

With the progression of neuroscience, the neurodevelopmental hypothesis of schizophrenia was formulated, which included educated guesses on the distinct roles of cortical and subcortical dopaminergic systems in the brain. The neurodevelopmental models posit that genetic and environmental risk factors act during prenatal, perinatal, and early adolescence periods, thus altering the developmental trajectory and leading to the onset during adolescence and young adulthood.\[[@ref1]\] The idea that adult-onset disorder could have its origin in neurodevelopment was supported by the studies of primates that showed that neonatal lesions can have delayed effects on behavior. The neurodevelopmental hypothesis has notably received much subsequent support from epidemiological, developmental, and neurological studies and has been the dominant paradigm for schizophrenia research over the past two decades.\[[@ref2]\]

Endophenotypes are the measurable biological (physiological, biochemical, and anatomical features), behavioral (psychometric pattern), or cognitive markers that are found more often in individuals with a disease than in the general population.\[[@ref3]\]

Endophenotypes reflects disease liability-associated variants in structural and functional magnetic resonance images, neurophysiological sensory processing measures, and because many endophenotypes are present before the disease onset and in individuals with heritable risk for disease such as unaffected family members, they can be used to help diagnose and search for causal association in disorders like schizophrenia.\[[@ref4]\]

Visual sensory processing deficits have been consistently documented in schizophrenia using the visual evoked potential (VEP) technique.\[[@ref5][@ref6]\]

VEP is an objective, noninvasive, simple, low-cost technique used to evaluate the functional integrity of the visual system and graphically illustrates cerebral electrical potentials produced by the occipital cortical areas evoked visually.\[[@ref5]\]

Quite a few studies\[[@ref7][@ref8][@ref9]\] have shown impairment of VEPs in patients of schizophrenia as compared to healthy controls in the past. The early marker of this impairment has been hypothesized in the variations of topographical form of P100 component of VEP. Based on this proposition, we designed a study for identifying the potential of this specific endophenotype provided with some degree of association, if any for schizophrenic patients. This may provide us the unique opportunity to endorse the support and strength of neurodevelopmental. Such a preliminary study has not been attempted so far as the literature could be traced in this part of the subcontinent.

MATERIALS AND METHODS {#sec1-2}
=====================

Setting {#sec2-1}
-------

Recruitment of the sample was carried out at the inpatient and outpatient services unit in department of psychiatry affiliated to tertiary health-care multispecialty teaching hospital at a rural-based institute in the state of Maharashtra.

Study design {#sec2-2}
------------

The study was an observational, noninterventional, hospital-based study.

Study population {#sec2-3}
----------------

Twenty patients of schizophrenia were investigated for VEP as soon they were cooperative and their psychomotor activity normalized. The average duration of disease in all cases was \>10 years. Only those patients were selected who were adherent to medication and showed good compliance. The severity of schizophrenia was assessed by Positive and Negative Symptoms Assessment Scale (PANSS) as well as Clinical Global Impression Severity Assessment Scale (CGI--SS).

The study was approved by ethics committee of institution (IEC, MGIMS). We obtained a written informed consent from all the study participants before enrolling them in the study. Only those patients were selected who fulfilled inclusion and exclusion criteria.

Inclusion criteria were age 30--65 years, either gender (male or female), chronicity of the disease \>10 years, presence of family history of schizophrenia in first- or second-degree relative, diagnosed cases of schizophrenia with predominant positive or negative symptoms (using International Classification of Disease-10 \[ICD-10\], Diagnostic and Clinical Research DCR criteria),\[[@ref10]\] those patients who are physically stable enough to undergo neurophysiological (VEP) evaluation.

Exclusion criteria were subnormal intelligence, any history of visual impairment beyond corrected-to-normal vision, organic brain disorder, mental retardation, or significant medical illness, history of comorbid diagnosed neurological disorder such as epilepsy or neurodegenerative disorders, history of head injury or having undergone recent neurosurgery, significant risk of suicidal or homicidal behavior, Whosoever refused to be a part of our study for any reason after due explanations for obtaining consent.

All participants reported normal or corrected-to-normal vision; where possible, this was corroborated by medical records.

Tools of assessment included semi-structured pro forma for sociodemographic and clinical profile, ICD criteria for diagnosing schizophrenia, PANSS scale, CGI scale, and pattern reversal VEP (PRVEP).

### Sociodemographic and clinical profile sheet {#sec3-1}

This was modified from the sociodemographic and clinical profile sheet used routinely in the department of psychiatry. The pro forma elicited information on age, sex, mother tongue, marital status, occupation, education status, family type, locality, source of referral, and clinical variables such as past medical illness, treatment history, substance use, and family history of psychiatric illness.

### International classification of disease 10^th^ revision (diagnostic and clinical research criteria) for the diagnosis of schizophrenia {#sec3-2}

The 10^th^ revision of the International Classification of Diseases by the World Health Organization was used. Patients who were diagnosed with schizophrenia as per the criteria of this manual were recruited into the study.

### Positive and negative symptoms assessment scale {#sec3-3}

It is a medical scale used for measuring symptom severity of patients with schizophrenia.\[[@ref11]\] Data gathered from this assessment procedure are applied to the PANSS ratings. Each of the 30 items is accompanied by a specific definition as well as detailed anchoring criteria for all seven rating points. These seven points represent increasing levels of psychopathology were as follows: 1 -- absent, 2 -- minimal, 3 -- mild, 4 -- moderate, 5 -- moderate-severe, 6 -- severe, and 7 -- extreme. To assess a patient using PANSS, an approximately 45-min clinical interview is conducted. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Of the 30 items included in the PANSS, 7 constitute a positive scale, 7 a negative scale, and the remaining 16 a General Psychopathology Scale. The scores for these scales are arrived at by summation of ratings across component items.

### Clinical global impression-severity scale {#sec3-4}

It is a 7-point scale that requires the clinician to rate the severity of the patient\'s illness at the time of assessment, relative to the clinician\'s past experience with patients who have the same diagnosis.\[[@ref12]\] Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

The CGI rating scales are commonly used measures of symptom severity, treatment response, and the efficacy of treatments in treatment studies of patients with mental disorders.

### Pattern reversal visual evoked potential recording {#sec3-5}

PRVEPs were performed in adherence to the standardized methodology of International Federation of Clinical Neurophysiology Committee Recommendations\[[@ref13]\] and International Society for Clinical Electrophysiology of Vision Guidelines\[[@ref14]\] and montages were kept as per 10--20 International System of EEG Electrode placements.\[[@ref15]\]

The stimulus configuration consisted of the transient pattern reversal method, in which a black and white checkerboard is generated (full field) on a VEP monitor by an electronic pattern regenerator inbuilt in an evoked potential recorder (RMS EMG EP MARK II manufactured by Recorders and Medicare Systems, Chandigarh). The recording was done monoculary for the left and right eyes separately with the subject wearing corrective glasses if any during the test.

Typical visual evoked potential waveform {#sec2-4}
----------------------------------------

The starting point of VEP waveform is stimulus onset. The typical PRVEP waveform consists of the earliest negative peak (N1 or N70), succeeded by a large positive peak (P1 or P100) and followed by another negative peak (N2 or N155) \[[Figure 1](#F1){ref-type="fig"}\]. Positive wave P100 is shown with downward polarity and the negative waves are shown with upward polarity in the recording. P100, the prominent attribute of PRVEPs, is the most consistent and invariable peak.

![Normal pattern reversal visual evoked potential waveform](IPJ-26-155-g001){#F1}

RESULTS {#sec1-3}
=======

A total of 20 patients of schizophrenia were recruited for the study. All of these patients were able to complete their study. The patients were not able to complete the study due to irregular follow-up, noncompliance, or refusal to participate were excluded.

The PRVEP investigation was performed on 20 (11 males and 9 females) patients with schizophrenia, aged 35--60 (mean 45.95 ± 10.14) years.

The mean score on CGI for the patients was 6.82 ± 1.25The mean score on PANSSFor positive subset of patients was: 54.78 ± 9.52For negative subset of patients was: 34.56 ± 11.12.

Qualitative analysis of VEP waveform in schizophrenic patients demonstrated abnormal waveform morphology in 14/20 (70%) of the study population and all of them were the chronic and severe cases. A few illustrations of atypical waveform in our study participants have been represented in Figures [2](#F2){ref-type="fig"}--[6](#F6){ref-type="fig"}. Six of 20 cases (30%) had normal PRVEP waveform morphology.

![Visual evoked potential record of a patient showing waveform with an atypical shape in the form of extinguished second negative component of negative--positive-negative complex (altered waveform)](IPJ-26-155-g002){#F2}

![Visual evoked potential record showing abnormal waveform morphology in the form of lack of differentiation of the evoked complex](IPJ-26-155-g003){#F3}

![Visual evoked potential record showing improper waveform morphology such that the three waves (negative--positive-negative complex) could not be identified](IPJ-26-155-g004){#F4}

![Visual evoked potential record shows the absence of P100 waveform morphology](IPJ-26-155-g005){#F5}

![Visual evoked potential record demonstrating poor reproducibility in the form of variable morphologies of waveform, thereby making it difficult to superimpose](IPJ-26-155-g006){#F6}

DISCUSSION {#sec1-4}
==========

Robust deviations in P100 component of the VEP including its topography have not been aptly and avidly reported in the literature.

A meager number of researchers have reported significant relationships between schizophrenic symptom patterns and EP parameters. Shagass\[[@ref16]\] showed that chronic, psychotic, and less depressed schizophrenic patients exhibited diminished shape variability of wave in the first 100 ms after visual stimulus compared with other schizophrenic patients.

Topographical differences in the location of abnormalities, depending on the patient\'s clinical symptoms have been observed when flash VEPs were recorded in normal and unmedicated schizophrenic patients using visual stimuli of differing intensities.\[[@ref17]\]

Our results are in close agreement with earlier studies where P1 component deficit has been identified in chronic patients\[[@ref7][@ref8][@ref9]\], and they have focused on the time course of these low-level visual processing deficits. In particular, it was revealed by topographic modulations in the VEP and demonstrated that P1 deficit follows from a change in the configuration of the underlying brain network.\[[@ref9]\]

PRVEP waveform abnormalities in schizophrenic patients have been previously ascribed\[[@ref18][@ref19][@ref20]\] to defects within dorsal visual stream structures on the basis of its topographic distribution, estimated sources, and relative sensitivity to luminance contrast. This notion is in solid agreement with studies\[[@ref21][@ref22][@ref23][@ref24]\] demonstrating inadequacies in visuospatial functions in such patients.

Our study is bestowed with qualitative morphometric analyses of VEP waveform abnormalities with regard to clinical symptom ratings which we found in predominantly severe patients of schizophrenia. Distorted, altered waveform morphology was found in 14/20 (70%) of cases explicitly all of whom belonged to the group of severe and chronic cases.

Six of our VEP records out of 14 (42.85%) showed abnormal waveform morphology in the form of lack of differentiation of the evoked complex so that the three waves (negative--positive-negative \[NPN\] complex) could not be identified and the parameters (namely, latencies and amplitude) could not be evaluated. In other 5 out of 14 (35.71%) VEP records, we noted a distinct waveform with an atypical shape in the form of extinguished second negative component of (NPN) complex (altered waveform). The hallmark of VEP which is (NPN complex was found to be extinguished in 3 of 14 (21.42%) cases. These are very unique findings of VEP as none of the study previously conducted could specifically pinpoint for any of such distinct qualitative, morphometric abnormality in patients of schizophrenia. Such distinct morphometric qualitative finding may need another look from the vantage point of speculation considering its potential role in diagnosis of schizophrenia.

There are at least two issues that still remain unsettled. First, the specificity of this deficit (and suitability as an endophenotype) is yet to be established, with evidence for altered P100 waveform in other clinical populations. Second, it remains unknown whether schizophrenia patients exhibit intact functional modulation of the P100 VEP component; an aspect that may assist in distinguishing effects specific to schizophrenia. On applying electrical neuroimaging analyses to VEPs from chronic schizophrenia patients and healthy controls in response to variation in the parafoveal spatial extent of stimuli, it was found that healthy controls demonstrated robust modulation of the VEP strength and topography as a function of the spatial extent of stimuli during the P1 component. By contrast, no such modulations were evident at early latencies in the responses from patients with schizophrenia. Source estimations have localized these insufficiencies to the left precuneus and medial inferiorparietal cortex. These findings provide insights on potential underlying low-level impairments in schizophrenia.

The study of morphological characteristics of the waveform generated in pattern-reversal VEPs is probably capable of elucidating the abnormalities in brain network dynamics relevant to the visual information-processing deficits in schizophrenia patients. In contrast to P50 and P300 event-related potentials (ERPs), however, the results of VEP studies in schizophrenia patients are more consistent, promising, and reliable too.

CONCLUSION {#sec1-5}
==========

To sum up, this study clearly offers the contribution of qualitative, morphometric analyses of VEP as potential endophenotype which has been revealed as unique wave patterns in evoked responses obtained from the patients. Atypical P100 waveform morphological abnormalities unveiled in cases of schizophrenia was the conspicuous finding of this study that was undiscovered till date. Therefore, our results show that VEP waveform has a promising potential for emerging as a new diagnostic electrophysiological biomarker in doting the entity of schizophrenia.

Limitation of the study {#sec2-5}
-----------------------

No study is not devoid of limitations if it is analyzed critically. This endophenotypic study despite being having the proband(s) of a positive history of psychosis in the first-degree relative; we failed to get their chromosomal linkage analyses which would have otherwise raised our understanding (if any) in providing the clues for further missing threads for etiopathogenesis of enigmatic disorders like schizophrenia.

Suggestions for future {#sec2-6}
----------------------

In future, using multicentric, longitudinal, multivariate, long-term, prospective cohort analysis in a large sample group from both hospital and community based on database should be planned to reaffirm if endophenotype cumulative factors can have direct relationship on predicting age, course, and outcome of schizophrenia.
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